4//SEC Filing
PROEHL GERALD T 4
Accession 0001654954-25-007736
CIK 0000034956other
Filed
Jul 2, 8:00 PM ET
Accepted
Jul 3, 8:11 AM ET
Size
15.3 KB
Accession
0001654954-25-007736
Insider Transaction Report
Form 4
PROEHL GERALD T
Director
Transactions
- Award
Stock Option (right to buy)
2025-07-01+80,000→ 80,000 totalExercise: $5.75From: 2026-07-01Exp: 2035-07-01→ Common Stock (80,000 underlying)
Holdings
- 1
Stock Option (right to buy)
Exercise: $9968.00From: 2019-05-01Exp: 2028-05-01→ Common Stock (1 underlying) - 1
Stock Option (right to buy)
Exercise: $1056.00From: 2021-05-01Exp: 2030-05-01→ Common Stock (1 underlying) - 4
Stock Option (right to buy)
Exercise: $992.00From: 2023-06-09Exp: 2032-06-09→ Common Stock (4 underlying) - 31,654
Pre-Funded Warrant
Exercise: $0.01From: 2024-08-08→ Common Stock (31,654 underlying) - 1,667
Common Stock
- 4
Stock Option (right to buy)
Exercise: $3200.00From: 2022-06-10Exp: 2031-06-10→ Common Stock (4 underlying) - 100,000
Stock Option (right to buy)
Exercise: $5.94From: 2025-12-10Exp: 2034-12-10→ Common Stock (100,000 underlying) - 16,660
Warrant
Exercise: $4.50From: 2024-08-08→ Common Stock (16,660 underlying)
Footnotes (2)
- [F1]The pre-funded warrant has no expiration date.
- [F2]The warrant will expire on the earlier of (i) thirty (30) trading days following the date of the Issuer's initial public announcement of topline data from its Phase 3 LEVEL Study (LEVosimendan to Improve Exercise Limitation in PH-HFpEF Patients) (NCT05983250 ) (the "Topline Data Announcement"); (ii) proportionally upon the exercise of the Reporting Person's pre-funded warrant issued on August 8, 2024, if such exercise is prior to the Topline Data Announcement; and (iii) August 8, 2029.
Documents
Issuer
TENAX THERAPEUTICS, INC.
CIK 0000034956
Entity typeother
Related Parties
1- filerCIK 0001279191
Filing Metadata
- Form type
- 4
- Filed
- Jul 2, 8:00 PM ET
- Accepted
- Jul 3, 8:11 AM ET
- Size
- 15.3 KB